Leucid Bio
Chris Davis is a Senior Scientist at LEUCID BIO since November 2022, with previous experience as a PhD student at King’s College London from October 2018 to December 2022, focusing on bioconjugation reagents for cancer imaging and CAR T-cell tracking. Prior to this, Chris was a Master’s student at Queen's University Belfast, conducting an in vitro assessment of novel cancer therapies, and held the role of Immunobiology Research Associate at Autolus Ltd., where research focused on the immunotherapy landscape for prostate cancer. Chris also completed an MSc in Immunology and a BSc (Hons) in Biomedical Science from St George's, University of London.
Leucid Bio
1 followers
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.